Spruce Biosciences
Clinical trials sponsored by Spruce Biosciences, explained in plain language.
-
New hope for kids with rare hormone disorder: drug may cut steroid doses
Disease control TerminatedThis study tested an experimental drug called tildacerfont in 67 children aged 2 to 17 with congenital adrenal hyperplasia (CAH), a genetic condition that disrupts hormone production. The goal was to see if adding this once-daily pill to standard steroid treatment could improve d…
Phase: PHASE2 • Sponsor: Spruce Biosciences • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
PCOS drug trial halted early: did tildacerfont lower hormones?
Disease control TerminatedThis study tested a drug called tildacerfont in 27 women with polycystic ovary syndrome (PCOS) who had high levels of adrenal androgens (hormones). The goal was to see if the drug could safely lower these hormones. The trial was stopped early, so results are limited.
Phase: PHASE2 • Sponsor: Spruce Biosciences • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug aims to cut steroid use in rare hormone disorder
Disease control TerminatedThis study tested a daily tablet called Tildacerfont in 100 adults with classic congenital adrenal hyperplasia, a condition where the body can't make certain hormones properly. The goal was to see if the drug could safely reduce the high doses of steroids patients need to take. T…
Phase: PHASE2 • Sponsor: Spruce Biosciences • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC